These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18715920)

  • 1. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.
    Goethals O; Clayton R; Van Ginderen M; Vereycken I; Wagemans E; Geluykens P; Dockx K; Strijbos R; Smits V; Vos A; Meersseman G; Jochmans D; Vermeire K; Schols D; Hallenberger S; Hertogs K
    J Virol; 2008 Nov; 82(21):10366-74. PubMed ID: 18715920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
    Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
    Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
    Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA
    J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
    Bar-Magen T; Sloan RD; Donahue DA; Kuhl BD; Zabeida A; Xu H; Oliveira M; Hazuda DJ; Wainberg MA
    J Virol; 2010 Sep; 84(18):9210-6. PubMed ID: 20610719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
    Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
    Hombrouck A; Voet A; Van Remoortel B; Desadeleer C; De Maeyer M; Debyser Z; Witvrouw M
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2069-78. PubMed ID: 18378713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).
    Shimura K; Kodama E; Sakagami Y; Matsuzaki Y; Watanabe W; Yamataka K; Watanabe Y; Ohata Y; Doi S; Sato M; Kano M; Ikeda S; Matsuoka M
    J Virol; 2008 Jan; 82(2):764-74. PubMed ID: 17977962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
    Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resistance to integrase inhibitors].
    Garrido C; de Mendoza C; Soriano V
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():40-6. PubMed ID: 19572425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.
    Fikkert V; Van Maele B; Vercammen J; Hantson A; Van Remoortel B; Michiels M; Gurnari C; Pannecouque C; De Maeyer M; Engelborghs Y; De Clercq E; Debyser Z; Witvrouw M
    J Virol; 2003 Nov; 77(21):11459-70. PubMed ID: 14557631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
    Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
    AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
    Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
    AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to HIV integrase inhibitors.
    Mesplède T; Quashie PK; Wainberg MA
    Curr Opin HIV AIDS; 2012 Sep; 7(5):401-8. PubMed ID: 22789986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
    Margot NA; Hluhanich RM; Jones GS; Andreatta KN; Tsiang M; McColl DJ; White KL; Miller MD
    Antiviral Res; 2012 Feb; 93(2):288-296. PubMed ID: 22197635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
    Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
    J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.